NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- KEAP1 Gene Mutation
- NFE2L2 Gene Mutation
- Non -Small Cell Lung Cancer
- Non-Squamous Non-Small Cell Neoplasm of Lung
- Non Squamous Non Small Cell Lung Cancer
- NRF2 Mutation
- Type
- Interventional
- Phase
- Early Phase 1
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: Stage IV, 1L Nonsquamous NSCLC patients to be screened for KEAP1 or NRF2(NFE2L2) gene mutationsMasking: None (Open Label)Primary Purpose: Screening
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04698681
- Collaborators
- Not Provided
- Investigators
- Study Director: Emil Kuriakose, MD Calithera Biosciences, Inc
Get Well Soon